This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HOB-294

Hisamitsu Pharmaceutical Co., Inc.

Drug Names(s): oxybutynin hydrochloride, transdermal oxybutynin, Neoxy (Japan)

Description: HOB-294 is a transdermal therapeutic formulation developed as a tape formulation which contains oxybutynin hydrochloride and uses Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. Hisamitsu has been developing this product in the expectation that its drug efficacy will last through the stable maintenance of drug levels in the blood.

Oxybutynin has a dual mechanism of action. Contraction of the smooth muscle of the bladder is stimulated by the release of acetylcholine by the nerves within the bladder and the attachment of the acetylcholine to receptors on the surface of the muscle cells. Oxybutynin suppresses involuntary contractions of the bladder's smooth muscle (spasms) by competitively blocking the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor (M1 may play a role in acetylcholine release). Oxybutynin also directly relaxes the bladder's outer layer of muscle (the detrusor muscle) as a calcium antagonist, though this is thought to occur at higher concentrations.

Deal Structure: HOB-294 was originally developed by Hisamitsu.

In December 2012, Hisamitsu Pharmaceutical and Asahi Kasei Pharma announced that they have concluded a Joint Sales Agreement in Japan for HOB-294. Under the terms of this agreement, Hisamitsu will obtain manufacturing and sales approval for the product, and the two companies will subsequently carry out joint sales activities. After the product is launched on the market, each company will carry out independent product distribution and information provision/gathering activities under a one-brand, two-channel setup.

Partners: Asahi Kasei Corporation


HOB-294 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug